This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Around 50% of people with APKD will be in end-stage kidney disease and require dialysis or transplantation by the age of 60 in PKD1 and the age of 75 in PKD2. There is great variability in the age of onset of renal failure (1) .
  • predictors of more rapid progression to renal failure include the following: (1)
    • earlier age at diagnosis
    • male sex
    • sickle cell trait
    • PKD1 genotype
    • larger or rapidly increasing kidney size
    • gross haematuria
    • hypertension
    • being black
    • increasing proteinuria

  • the most lethal extrarenal manifestations of ADPKD are intracranial aneurysms, which have been found to be present in up to 40% of ADPKD patients (2). Patients with mutations in the 5' region of PKD1 are more likely to have aneurysm rupture. (3)

 

Reference:

  1. Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015 May 16;385(9981):1993-2002.
  2. Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018 Dec 6;4(1):50.
  3. Rossetti S, Harris PC. The genetics of vascular complications in autosomal dominant polycystic kidney disease (ADPKD). Curr Hypertens Rev. 2013 Feb;9(1):37-43.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.